Histone deacetylase inhibitors (HDACIs) : multitargeted anticancer agents

Discusses the use of Histone deacetylase (HDAC) inhibitors as multitargeted therapies for malignancy. Outlines the pharmacology and mechanisms of action of HDAC inhibitors while covering the safety and efficacy of these compounds in clinical studies to date. Describes current HDAC inhibitors in clinical trials : Vorinostat, Depsipeptide, Entinostat, and Valproic acid. Notes other novel HDAC inhibitors. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.